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Summary
Objective: To examine the performance of the Norwegian version of the AUSCAN Index as a disease-speciﬁc health status measure in
patients with hand osteoarthritis (OA).
Methods: One hundred and ninety-nine patients with clinical hand OA (mean (SD) age 61.7 (5.7) years, 18 (9%) males) underwent
a comprehensive examination including joint status, examination of grip strength and completion of several self-reported health status
questionnaires. The Australian/Canadian OA hand index (AUSCAN) captures three different dimensions of hand OA: pain (5 items), stiffness
(1 item), and difﬁculties with daily activities (9 items). Our pre-study hypothesis was to identify AUSCAN as a speciﬁc hand measure with
strong correlations to hand measures and lower correlations to other general measures of health.
Results: Patient completion of the AUSCAN Index was similar or better than other measures. The internal consistency of the AUSCAN was
excellent. The pain and physical dimension of AUSCAN correlated substantially to each other and moderately to the stiffness scale. The
AUSCAN physical scale correlated moderately to substantially to other measures, the highest correlation being seen with the Arthritis Impact
Measurement Scale (AIMS) 2 hand and ﬁnger function scale (rZ 0.73). The standardised differences between patients with and without
radiographic abnormalities were numerically larger for the AUSCAN pain and physical scales than for other measures.
Conclusion: The Norwegian version of the AUSCAN has an acceptable clinimetric performance and is a suitable tool for assessment of hand
OA.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Assessment of health status and development of instru-
ments to evaluate quality of life and health status in patients
with rheumatic diseases is of great importance for clinical
trials and clinical practice, as well as for assessment of the
burden of diseases. Both generic and disease-speciﬁc
instruments are widely used in rheumatoid arthritis (RA)
and related inﬂammatory diseases and are also increasingly
used in osteoarthritis (OA). Disease-speciﬁc instruments
have been developed for assessment of hip and kneeOA1e4.
The advantage of such condition speciﬁc measures is that
they usually have better abilities to capture the health
problems that are speciﬁc to the condition and have better
discriminatory abilities and responsiveness.
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attention from researchers, clinicians and politicians be-
cause of a growing elderly population with increased
occurrence of OA. The disease incurs a major burden both
on the individual and on the society5,6. OA exists in both
a localised and generalised form. Hand OA may occur as
a localised type but is more frequently part of a generalised
type of the disease with involvement of the carpometacarpal
(CMC), peripheral interphalangeal (PIP) and distal in-
terphalangeal (DIP) joints, leading to pain, stiffness and
disability7,8.
The consensus work of Outcome Measures in Rheuma-
tology (OMERACT) recommended pain, physical function
and patient global assessment as core measures of
assessment of knee, hip and hand OA in clinical trials9.
Assessment of hand OA has received less attention than
evaluation of OA in the hips and knees, but some
instruments have been developed and validated. The
Dreiser algofunctional index Functional Index for Hand
Osteoarthritis (FIHOA) is an investigator administered 10-
question functional index10,11. The Cochin/Duruoz Hand
Functional Disability Scale is an 18-item questionnaire,
developed for rheumatoid hands, which recently also has
been evaluated for hand OA12,13. Score for the Assessment1
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Hands (SACRAH) is a newly established questionnaire
developed to evaluate hand function, stiffness and pain in
patients with OA and RA14. Maheu and co-workers10
developed a clinical scoring system done by weekly self-
assessment of the patient with hand OA. Another approach
has been to use the Canadian Occupational Performance
Measure (COPM)15.
The Australian/Canadian OA hand index (AUSCAN) has
been developed with a structure similar to the Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC). AUSCAN is a patient-reported 15-item ques-
tionnaire providing information on three health dimensions:
pain, stiffness and difﬁculties with daily activities16,17. The
instrument has now been translated to Norwegian accord-
ing to standardised procedures.
The aim of this study was to examine the performance of
the Norwegian version of the AUSCAN as a disease-
speciﬁc health status measure in patients with hand OA. In
particular, we wanted to address whether the AUSCAN
Index, in accordance with the expectations of a speciﬁc
hand measure, had strong or substantial correlations to
hand measures of similar dimensionality and weaker
correlations to other measures, and had better discrimina-
tory abilities than other health status measures.
Materials and methods
PATIENTS
This study included 199 patients between 50 and 70 years
of age with clinical hand OA with a wide spectrum ranging
from isolated CMC OA to generalised erosive OA (mean
(SD) age 61.7 (5.7) years, 18 (9%) males), who previously
had been referred to the rheumatologic outpatient de-
partment. One hundred and sixty-six (82.4%) of the patients
fulﬁlled the American College of Rheumatology (ACR)
classiﬁcation criteria for hand OA and 33 (17.6%) had
clinical hand OAwithout formally fulﬁlling these classiﬁcation
criteria (Table I)7,18. Radiographic OA abnormalities (Kellg-
ren and Lawrence grade 2 or more)19 of the ﬁnger joints were
observed in 183 (92%). Twenty of the patients (10%) also
fulﬁlled the clinical and radiographic ACR classiﬁcation for
hip OA20 and 149 (75%) fulﬁlled the clinical ACR classiﬁca-
tion criteria for knee OA18,21. Ninety-three (46.7%) were
current users of nonsteroidal anti-inﬂammatory drugs
Table I
Number (%) of patients (nZ 199) fulfilling the ACR hand OA
classification criteria18
Item no. Item n (%)
1 Hand pain, aching or stiffness 199 (100)
2 Hard tissue
enlargement of two or more
of the 10 selected joints*
164 (82.4)
3 Hard tissue enlargement
of two or more DIP joints
165 (83.3)
4 Fewer than three swollen
MCP joints
197 (99.0)
5 Deformity of at least 10 of
the selected joints*
153 (77.3)
Fulﬁlment of all items 139 (69.8)
Fulﬁlment of ACR criteria
for hand OA
166 (82.4)
*The 10 selected joints are bilateral DIP and PIP II, III and CMC.(NSAIDs), 71 (35.7%) were previous users and 35 (17.8%)
reported not to have used NSAIDs ever. Eleven patients had
already undergone a hip replacement, including four with
bilateral prosthesis. Seven patients had received knee
prosthesis at the time of examination. Patients with other
rheumatic diseases such as rheumatoid arthritis, psoriatic
arthritis, systemic connective diseases and spondylarthro-
pathies were not included. Exclusions were based on both
clinical evaluation as well as fulﬁlment of respective
classiﬁcation criteria.
EXAMINATIONS AND INSTRUMENTS
After informed consent, patients met for a complete
assessment of their joint status and functional status. The
clinical examination included relevant joint assessment
(shoulders, acromio-clavicular joint, elbows, wrists, CMC
joints, metacarpophalangeal (MCP), PIP, DIP joints, spine,
hips, knees, ankles and feet), and the patients completed
several self-reported health status questionnaires. All
interventions were conducted during day time, mostly
between 09:00 a.m. and 01:00 p.m.
AUSCAN
The AUSCAN is a disease-speciﬁc health status mea-
sure for hand OA measuring pain (5 items), stiffness
(1 item) and difﬁculties with daily activities (9 items)
(Table II). It exists as a Numerical Rating Scale (NRS),
a visual analogue scale (VAS) (10 cm horizontal) and
a Likert version17. We used the latter, which gives the
patient a choice of ﬁve response options (none, mild,
moderate, severe, extreme (0e4)) within each of the 15
items. The pain dimension assesses the amount of hand
pain at rest, when gripping, lifting, turning or squeezing
objects. The stiffness dimension asks for stiffness after
wakening during the last 48 h. The physical dimension is
capturing difﬁculties with turning taps and a round doorknob
or handle, doing buttons, fastening jewellery, opening a new
jar, carrying a full pot with one hand, peeling vegetables/
fruits, picking up large, heavy objects and wringing out
washcloths3,16,17,22 (Table II). Subscale scores were
calculated by simple summation of the assigned values
scored on component items. We chose to present
normalised data with a score range of 0e10, i.e., the sum
score of each of the 0e4 item scores within each dimension
(pain range 0e20, stiffness 0e4, physical function 0e36) is
multiplied by a correction factor (pain: 0.5, stiffness: 2.5,
physical function: 0.278). The translation procedures
followed standardised guidelines. The AUSCAN was
Table II
The items of AUSCAN within the three dimensions: pain, stiffness
and physical functioning
Pain Stiffness Physical function
At rest After ﬁrst
wakening
Turning taps
Gripping Turning a doorknob or handle
Lifting Doing buttons
Turning Fastening jewellery
Squeezing Opening a new jar
Carrying a full pot with one hand
Peeling vegetables/fruits
Picking up large, heavy objects
Wringing out washcloths
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translators to Norwegian and then translated back to
English by two independent translators whose mother
tongue was English. Consensus on controversies after the
different translation phases was established in a multidisci-
plinary committee. This committee also considered cultural
adaptation of some of the items, but concluded on using
rather straightforward translations of all the items.
WOMAC
WOMAC is a widely used condition speciﬁc instrument
for assessment of hip and knee OA. It is a multidimensional
self-administered measure capturing pain (5 items), stiff-
ness (2 items) and physical function (17 items)1,2,23. This
questionnaire exists also in a VAS, a Likert and an NRS
version. The Likert version was used in this study and the
scores were computed similar to the AUSCAN scores, i.e.,
normalised to a score range of 0e103,24e26.
OTHER SELF-REPORTED MEASURES
The Modiﬁed Health Assessment Questionnaire (MHAQ)
is an 8-item modiﬁcation of the original 20-item Stanford
Health Assessment Questionnaire (HAQ) . The patients are
asked about their ability to perform daily activities and to
indicate the difﬁculty from grade 1 ‘‘without any difﬁculty’’ to
grade 4 ‘‘unable to do’’. A meanMHAQ score is calculated27.
Arthritis Impact Measurement Scales (AIMS) 2 is
a multidimensional arthritis speciﬁc health status measure.
The ﬁrst 57 items are broken into 12 scales: mobility (5
items), walking and bending (5 items), hand and ﬁnger
function (5 items), arm function (5 items), self care tasks (4
items), household tasks (4 items), social activity (5 items),
support from family and friends (5 items), arthritis pain (5
items), work (4 items), level of tension (5 items), and mood
(5 items)28. The AIMS2 may be presented in a ﬁve-
component model (physical, affect, social interaction,
symptom (pain), and role (work)). Scores range from 0 to
10 (10 worst health).
Short form (SF)-36 is the most widely used generic health
status questionnaire, measuring eight important health
dimensions capturing physical function (10 items), role
limitations due to physical health (4 items), bodily pain (2
items), general health (5 items), vitality/energy (4 items), role
limitations due to emotional problems (3 items),mental health
(5 items) and 1 item on reported health transition. The SF-36
scores range from0 to 100, low scores indicate poor health29.VAS for joint pain and fatigue reﬂect the patient
assessment of these symptoms on a horizontal scale from
0 to 100 mm with no pain/fatigue and intolerable pain/
fatigue as the anchoring points.
Lorig et al.’s30 self-efﬁcacy scales measure the patients
perceived capability to perform actions to inﬂuence rheu-
matic pain (5 questions), physical function (9 items) and
other symptoms (6 items). Responses are measured on
a scale from 10 to 100 (very uncertainevery certain).
PERFORMANCE BASED TEST
Grip strength was measured in a standardised way by
hand-dynamometer (as the best performance out of two
attempts on each hand), without asking for the patients
dominant hand.
ETHICS AND DATA ANALYSES
All patients signed an informed consent form .The study
was approved by the data inspectorate and the local ethical
committee.
All data were analysed by SPSS (version 10.1). AUSCAN
scores as well as scores for other health status measures
were computed if at least 50% of the items within each
dimension were completed.
Correlations were examined by Pearson’s correlation
coefﬁcient. Our pre-study hypothesis was to identify
AUSCAN as a speciﬁc hand measure with strong correla-
tions (r R 0.70) to hand measures of similar dimensionality,
moderate to substantial correlations to general measures
within the same dimension of health (r between 0.30 and
0.70), and weak correlations (r% 0.30) to measures
capturing different dimensions.
We also examined how AUSCAN and other health status
measures differed across age groups and gender and
across subgroups of patients with different disease char-
acteristics (ACR classiﬁcation criteria and radiographic
ﬁndings). Group differences were examined by two-sample
t tests, and for the comparison of the magnitude of
discriminatory abilities differences were standardised
(difference divided by the standard deviation of the
difference).
Results
Table III shows the distribution of normalised AUSCAN
scores and other health status measures. CompletenessTable III
Distribution of normalised scores for AUSCAN, and other health status measures (nZ 199)
Number (%) with valid scores Mean 95% CI Lowest Highest Score (range)
AUSCAN pain 195 (98.0) 3.92 3.61, 4.22 0.00 10.00 0e10
WOMAC pain 195 (98.0) 3.60 3.26, 3.95 0.00 9.50 0e10
VAS pain 198 (99.5) 39.1 35.9, 42.2 0.00 96.0 0e100
AIMS2 pain 191 (96.0) 5.62 5.28, 5.96 0.00 10.00 0e10
AUSCAN stiffness 194 (97.5) 4.33 3.99, 4.66 0.00 10.00 0e10
WOMAC stiffness 196 (98.5) 4.07 3.74, 4.39 0.00 10.00 0e10
AUSCAN physical 197 (99.0) 4.20 3.88, 4.51 0.00 9.17 0e10
WOMAC physical 196 (98.5) 3.13 2.81, 3.45 0.00 9.00 0e10
AIMS2 physical 194 (97.5) 1.79 1.62, 1.96 0.00 5.92 0e10
AIMS2 hand and ﬁnger 195 (98.0) 3.06 2.73, 3.39 0.00 10.00 0e10
AIMS2 arm 194 (97.5) 1.03 0.82, 1.24 0.00 6.50 0e10
SF-36 physical 194 (97.5) 58.0 54.7, 61.4 0.00 100.0 0e100
MHAQ 197 (99.0) 1.48 1.43, 1.54 1.00 2.63 1e4
Grip strength 191 (96.0) 19.6 18.4, 20.8 5.00 52.0 n.a.
564 B. Slatkowsky-Christensen et al.: Performance of the Norwegian version of AUSCANregarding valid scores was similar or better than other
measures. The internal consistency of the scales was
excellent (Cronbach’s alpha for physical function 0.95, for
pain 0.93).
The pain and physical dimension of AUSCAN correlated
substantially to each other and moderately to the stiffness
scale (Table IV). The AUSCAN pain scale correlated
moderately to other pain measures, and also to WOMAC
stiffness and the physical scales (Table V). Moderate
correlation was also observed between the AUSCAN
stiffness and other measures of pain, stiffness and physical
function. The AUSCAN physical scale correlated moder-
ately to substantially to other measures. The highest
correlation for AUSCAN pain was with AIMS2 pain, and
for AUSCAN function was with AIMS2 hand and ﬁnger
function (Table V).
Elderly patients in general reported worse health than
younger patients, especially within the physical dimension,
whereas females reported worse health status than males
across all domains (Table VI). Statistical evidence partially
supported the pre-study hypothesis that disease-speciﬁc
measures of hand OA discriminate better than other
measures between patients with and without fulﬁlment of
the ACR classiﬁcation criteria for hand OA and radiographic
OA abnormalities of the ﬁnger joints (Table VI). Thus, the
standardised differences between patients with and without
fulﬁlment of the classiﬁcation criteria were numerically
larger for the AUSCAN stiffness scale than for other
measures (Fig. 1) and also numerically largest for the
AUSCAN pain and physical scales between patients with
and without radiographic abnormalities (Fig. 2). Further-
more, statistically signiﬁcant differences between patients
with and without fulﬁlment of ACR classiﬁcation criteria
were detected by the AUSCAN stiffness subscale, the VA
pain scale and the AIMS2 hand and ﬁnger function
subscale (Table VI), and statistically signiﬁcant differences
between patients with and without radiographic OA abnor-
malities of the ﬁnger joints were only detected by the
AUSCAN pain and physical function subscales (Table VI).
Discussion
Hand OA is a frequent condition affecting a large
proportion of the adult population31. Patients with hand
OA referred to a department of rheumatology report levels
of disability and pain of the same magnitude as patients
with RA29. From this perspective, health status assess-
ments are important. The AUSCAN represents a new and
important approach in this area and this is one of the ﬁrst
studies to evaluate the performance of this instrument in
a non-English language. The current results indicate that
the Norwegian version of the AUSCAN performs well with
correlations to other instruments measuring various dimen-
sions of health according to the pre-study hypothesis,
supporting that it performs as a disease-speciﬁc measure of
hand OA.
Table IV





Physical 0.83 0.64 1.0Other studies have also shown that the AUSCAN both in
the Likert and VAS version shows acceptable levels of
validity and reliability and good responsiveness16,17. The
AUSCAN has been translated into several different lan-
guage forms for Australia, Austria, Canada (English,
French), Czech Republic, France, Finland, Germany, Israel
(Hebrew), Italy, Netherlands, New Zealand, Norway, Po-
land, Russia, Slovakia, South Africa (Afrikaans, English),
Spain, Sweden, Turkey and the USA (English, Span-
ish)16,17.
The performance of health status measures should
ideally include examination of their validity, feasibility and
sensitivity to change32. The present study supports the
theory that AUSCAN is a valid instrument in hand OA, both
regarding the construct and discriminatory validity. The
standardised differences between patients with and without
fulﬁlment of the classiﬁcation criteria for hand OA were
numerically larger for the AUSCAN stiffness scale than for
other measures and largest for AUSCAN pain and physical
scales between patients with and without radiographic
abnormalities (Figs. 1 and 2). Furthermore, the AUSCAN
Index was one of few measures to detect statistically
signiﬁcant differences between patients fulﬁlling and not
fulﬁlling ACR classiﬁcation criteria and having vs not having
radiographic evidence of hand OA. Taken collectively,
these data are generally supportive of the speciﬁcity of
the AUSCAN Index.
Feasibility of the AUSCAN Index is acceptable in terms of
number of items (15 items) and length of time for
completeness (approximately 3e5 min), and as demon-
strated by the high proportion of patients completing the
questionnaire (Table II).
Although AUSCAN Index responsiveness was not
evaluated in this study, responsiveness of the Index has
previously been examined16. The original validation study
conﬁrmed that the AUSCAN Index is responsive in all three
dimensions (pain, stiffness and physical function). Re-
sponsiveness has subsequently been demonstrated in
placebo-controlled trials of anti-inﬂammatory agents33,34.
The present study was performed in a large number of
patients of which the majority (O80%) fulﬁlled the ACR
classiﬁcation criteria for hand OA and the majority (O90%)
Table V
Correlations (Pearson’s correlation coefficient) between AUSCAN




WOMAC 0.48 0.43 0.48
VAS pain 0.61 0.48 0.58
AIMS2 0.64 0.48 0.56
SF-36 0.51 0.34 0.45
Stiffness scale
WOMAC 0.41 0.47 0.44
Physical scales
WOMAC 0.54 0.50 0.57
AIMS2 physical 0.51 0.43 0.58
AIMS2 hand and ﬁnger 0.57 0.44 0.73
AIMS2 arm 0.39 0.35 0.40
SF-36 0.43 0.32 0.49
MHAQ 0.56 0.47 0.65
Performance test
Grip strength 0.41 0.28 0.49
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Discriminatory abilities, evaluated by comparing health status scores between subgroups according to age, gender, fulfilment of ACR criteria
and presence of radiographic abnormalities (mean scores, P-values from two-sample t test)





















Pain 1.49 1.48 0.84 3.93 3.78 0.78 4.04 3.33 0.08 4.01 2.79 0.04
Stiffness 4.22 4.41 0.58 4.38 3.82 0.35 4.53 3.33 0.007 4.36 4.11 0.71
Physical 4.00 4.35 0.27 4.31 3.09 0.03 4.31 3.65 0.13 4.31 3.02 0.04
Pain scales
WOMAC 3.35 3.79 0.22 3.71 2.58 0.06 3.53 3.96 0.36 3.63 3.63 1.00
VAS pain 36.3 41.0 0.14 39.6 33.9 0.31 40.2 33.2 0.04 38.9 41.6 0.67
AIMS2 5.50 5.71 0.54 5.65 5.30 0.55 5.65 5.49 0.73 5.61 5.75 0.83
SF-36 40.2 39.4 0.68 39.5 43.7 0.37 39.3 42.7 0.35 40.0 37.6 0.64
Stiffness scale
WOMAC 3.75 4.30 0.10 4.17 3.06 0.05 4.05 4.07 0.97 4.08 4.20 0.86
Physical scales
WOMAC 2.90 3.30 0.24 3.21 2.36 0.13 3.14 3.09 0.92 3.16 3.11 0.94
AIMS2 physical 1.59 1.94 0.04 1.82 1.53 0.33 1.83 1.59 0.30 1.82 1.47 0.29
AIMS2 hand
and ﬁnger
2.90 3.18 0.41 3.13 2.30 0.16 3.18 2.44 0.04 3.13 2.11 0.12
AIMS2 arm 0.91 1.12 0.34 1.04 0.88 0.67 1.06 0.89 0.57 1.07 0.64 0.30
SF-36 61.9 55.2 0.05 57.3 65.8 0.15 58.2 57.1 0.81 57.7 57.9 0.98
MHAQ 1.49 1.48 0.92 1.49 1.39 0.29 1.50 1.39 0.15 1.48 1.50 0.91
Performance
test
Grip strength 20.4 19.0 0.25 18.2 34.4 19.3 21.2 0.26 19.2 23.8 0.06also had deﬁnite radiological OA abnormalities. Other
strengths of the study included the comprehensive data
collection using both condition speciﬁc and generic health
status measures as well as a thorough clinical examination
by the same trained physician. We were able to examine
the correlation of the three different health areas of the
AUSCAN Index with both self-reported and a performance
based hand function test. However, a limitation was that we
did not include other existing speciﬁc hand function
instruments10,12e15 in our study protocol. Further, the
cross-sectional design did not allow examination of the
Fig. 1. Standardised differences (difference divided by the standard
deviation of the difference) of various health status measures
between patients fulﬁlling (nZ 166) and not fulﬁlling (nZ 33) the
ACR classiﬁcation criteria for hand OA.responsiveness, but the patient cohort will be followed
longitudinally, giving future access to follow-up data on the
AUSCAN Index.
Patients with hand OA suffer from severe pain, stiffness
and disability. This patient group therefore represents
a challenge for both general practitioners and rheumatolo-
gists in their every day practice, as well as for the clinical
researcher. In the future, research on hand OA is expected
to focus on better longitudinal epidemiological studies and
improved interventions. For both these research directions
high performance disease-speciﬁc measures are required.
Fig. 2. Standardised differences (difference divided by the standard
deviation of the difference) of various health status measures
between patients with (nZ 183) and without (nZ 14) radiographic
OA abnormalities of ﬁnger joints.
566 B. Slatkowsky-Christensen et al.: Performance of the Norwegian version of AUSCANThe Norwegian translation of the AUSCAN Index is valid
and reliable, and is an important tool for the assessment of
patients with hand OA.
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